An observational study in Cataract, Shallow Anterior Chamber and Narrow Angle, sponsored by Zheng Qian. Status unknown at 1 site in China. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-12.
Sponsored by Zheng Qian · Observational
To investigate changes in anterior chamber angle configuration after phacoemulsification and intraocular lens (IOL) implantation with Swept-Source Optical Coherence Tomography (SS-OCT).
To investigate changes in anterior chamber angle configuration after phacoemulsification and intraocular lens (IOL) implantation in eyes with a shallow anterior chamber and narrow angle, compared with the eyes with normal anterior chamber and open angle using Swept-Source Optical Coherence Tomography (SS-OCT).
1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's planned enrollment of 64 is below the median of 81 across 484 observational studies indexed under Cataract.
Browse Cataract studies →Zheng Qian is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients who underwent phacoemulsification surgery in Eye Hospital of Wenzhou Medical University
ACD was less than 2.68mm. the anterior chamber angle width on gonioscopy≤Shaffer 2 .
Exclusion Criteria:
primary or secondary glaucoma, peripheral anterior synechiae, history of ocular surgeries
normal anterior chamber and open angle eyes underwent cataract surgery
Procedure: cataract surgery
shallow anterior chamber and narrow angle eyes underwent cataract surgery
Procedure: cataract surgery
The patients of both groups underwent cataract surgery
anterior chamber angle parameters increased
Time frame: 1 year
This study is status unknown, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zheng Qian